<DOC>
	<DOCNO>NCT01381822</DOCNO>
	<brief_summary>The primary objective : Dose escalation : 1 . To determine MTD DLT ( ) TH-302 use combination sunitinib . Dose expansion : 1 . To make preliminary assessment efficacy TH-302 combination sunitinib determine response rate progression-free survival subject advance RCC treat RP2D 2 . To assess safety TH-302 combination sunitinib determine recommend Phase 2 dose combination . The secondary objective : Dose expansion : 1 . To make preliminary assessment efficacy TH-302 combination sunitinib determine stable disease well rate , duration response overall survival subject advance RCC treat RP2D . The exploratory objective : 1 . To explore association serum hypoxia biomarkers efficacy endpoint .</brief_summary>
	<brief_title>Dose-Escalation Study TH-302 Combination With Sunitinib Treat Patients With Advanced Renal Cell Carcinoma , Gastrointestinal Stromal Tumors Pancreatic Neuroendocrine Tumors</brief_title>
	<detailed_description>This Phase 1 dose-escalation study use classic dose escalation design determine MTD TH-302 use combination sunitinib . The study divide two part complete succession determine recommend phase 2 dose ( RP2D ) dose expansion . Part A : The dose TH-302 escalate cohort 3-6 subject . The initial dose TH-302 240 mg/m2 . A Dose Level minus 1 2 build study event subject experience excessive toxicity Dose Level 1 . Dose escalation continue approximately 40 % increase previous dose level ; however low dose increase 20-39 % may implement consultation Investigators , Medical Monitor Sponsor percent increase dependent current dose level cumulative safety data . If subject experience DLT , 3 additional subject enrol dose level total 6 subject cohort . If additional DLTs observe , dose escalation resume . However , 2 6 subject within cohort experience DLT , dose consider exceed MTD . The MTD define next low dose level whereby 6 subject treat &lt; 1 subject experience DLT . The maximum dose TH-302 575 mg/m2 . The MTD base toxicity occur first cycle . TH-302 administered IV infusion 30-60 minute Days 8 , 15 22 42-day cycle ( 6 week ) . The dose sunitinib remain fix : 50 mg administer PO daily day 1 28 day 42-day cycle ( 6 week ) . On day sunitinib TH-302 administer , sunitinib administer least 2 hour least 2 hour completion TH-302 dose . Part B : Once MTD Part A determine , Part B commence . The initial dose TH-302 one dose level high MTD establish Part A . The dose TH-302 escalate cohort 3-6 subject . A Dose Level MTD establish Part A built study event subject experience excessive toxicity initial dose . Dose escalation continue approximately 40 % increase previous dose level ; however low dose increase 20-39 % may implement consultation Investigators , Medical Monitor Sponsor percent increase dependent current dose level cumulative safety data . If subject experience DLT , 3 additional subject enrol dose level total 6 subject cohort . If additional DLTs observe , dose escalation resume . However , 2 6 subject within cohort experience DLT , dose consider exceed MTD . The MTD define next low dose level whereby 6 subject treat &lt; 1 subject experience DLT . The MTD base toxicity occur first cycle . TH-302 administered IV infusion 30-60 minute Days 8 , 15 22 42-day cycle ( 6 week ) . The dose sunitinib remain fix : 37.5 mg administer PO daily day 1 28 42-day cycle ( 6 week ) . On day sunitinib TH-302 administer , sunitinib administer least 2 hour least 2 hour completion TH-302 dose . An additional 10 RCC subject enrol recommended phase 2 dose ( RP2D ) dose expansion portion study .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
	<mesh_term>Adenoma , Islet Cell</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>At least 18 year age Ability understand purpose risk study sign write informed consent form approve investigator 's IRB/Ethics Committee Pathologically confirm diagnosis advance RCC GIST disease progression intolerance imatinib mesylate ( dose escalation ) Unresectable locally advance metastatic pancreatic neuroendocrine tumor ( dose escalation ) Recovered reversible toxicity prior therapy Evaluable disease RECIST criterion ( least one target nontarget lesion dose escalation cohort ; least 1 target lesion dose expansion cohort ) ECOG performance status 0 2 Life expectancy least 3 month Acceptable liver function : Bilirubin le equal 1.5 time upper limit normal ( ULN ) AST ( SGOT ) ALT ( SGPT ) less equal 3.0 time ULN Acceptable renal function : Serum creatinine ≤ Upper Limit Normal , Acceptable hematologic status ( without hematologic support ) : ANC great equal 1500 cells/μL Platelet count great equal 100,000/μL Hemoglobin great equal 9.0 g/dL Acceptable cardiac function : Normal 12lead ECG ( clinically insignificant abnormality permit ) LVEF normal MUGA echocardiogram Urinalysis : No clinically significant abnormality Acceptable thyroid function All woman childbearing potential must negative serum pregnancy test subject must agree use effective mean contraception ( surgical sterilization use barrier contraception either condom diaphragm conjunction spermicidal gel IUD ) partner entry study 6 month last dose Prior therapy 2 myelosuppressive cytotoxic chemotherapy regimen ( include neoadjuvant adjuvant therapy ) Current use drug know cardiotoxicity know interaction sunitinib ( see product label ) Anticancer treatment radiation therapy , chemotherapy , target therapy ( erlotinib , lapatinib , etc . ) , immunotherapy , hormone antitumor therapy within 3 week prior study entry ( 6 week nitrosoureas mitomycin C ) Significant cardiac dysfunction : Cardiac event within 12 month prior treatment include MI severe/unstable angina , coronary/peripheral artery bypass graft , symptomatic CHF , cerebrovascular accident transient ischemic attack pulmonary embolism &gt; Grade 2 QTc prolongation Requirement antiarrhythmic Uncontrolled arrhythmias within past 6 month Angina pectoris require antianginal medication within past 6 month Clinically significant valvular heart disease Poorly control hypertension despite adequate blood pressure medication Seizure disorder require anticonvulsant therapy Known brain metastasis ( unless previously treat well controlled period great equal 3 month ) Other active malignancy , except adequately treat nonmelanoma skin cancer , situ cancer Severe chronic obstructive pulmonary disease hypoxemia ( require supplementary oxygen , symptom due hypoxemia oxygen saturation &lt; 90 % pulse oximetry 2 minute walk ) opinion investigator physiological state likely cause normal tissue hypoxia Major surgery , diagnostic surgery , within 4 week prior Day 1 , without complete recovery Active , uncontrolled bacterial , viral , fungal infection , require systemic therapy Prior therapy hypoxic cytotoxin Subjects participate investigational drug device study within 21 day prior study entry Known infection HIV active infection hepatitis B hepatitis C Subjects exhibit allergic reaction structural compound biological agent similar TH302 Females pregnant breastfeeding Concomitant disease condition could interfere conduct study , would , opinion investigator , pose unacceptable risk subject study Unwillingness inability comply study protocol reason</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>TH-302</keyword>
	<keyword>Advanced Renal Cell Carcinoma</keyword>
	<keyword>RCC</keyword>
	<keyword>Gastrointestinal Stromal Tumors</keyword>
	<keyword>GIST</keyword>
	<keyword>Phase 1</keyword>
	<keyword>Sunitinib</keyword>
	<keyword>Pancreatic Neuroendocrine Tumors</keyword>
	<keyword>PNET</keyword>
</DOC>